Office of Commercialization and Economic Development
Office of Technology Commercialization

Synthetic Peptide Mimetic for the Treatment of Cancer and Hematalogical Disorders

Technology #19-0178

Questions about this technology? Ask a Technology Manager

Download Printable PDF

David Williams
Managed By
Kyle Bartholomew
Commercialization Manager 919.962.5921
Patent Protection
Provisional Patent Application Filed

Researchers at UNC have recently developed a cell penetrating, synthetic peptide for the treatment of heamtological cancer, sickle cell anemia and ß-thalassemia. This peptide exerts its therapeutic effect by disrupting the MBD2:NuRD complex in human cells. Recent studies have indicated that disrupting MBD2:NuRD complex formation can inhibit DNA methylation, making this complex a target for potential alternatives to currently prescribed DNA methylation inhibitors. UNC researchers have demonstrated the effectiveness of this peptide in several leukemia models, and have demonstrated that this synthetic peptide is particularly effective against T-ALL. DNA methylation also plays a role in the gene silencing of fetal hemoglobin and as a result, this peptide presents a novel therapeutic approach to ß-hemoglobinopathies.<!–[if supportFields]><![endif]–>

Related Publications: